Lafora disease is a rare, inherited form of epilepsy that strikes previously healthy teenagers and causes progressive neurological decline. It belongs to a group of conditions called progressive myoclonus epilepsies, and it is among the most severe. Fewer than one in a million people worldwide are affected, and median survival from symptom onset is about 11 years.
How Lafora Disease Develops
The disease is caused by mutations in one of two genes: EPM2A or EPM2B. These genes produce two proteins that work together to manage how the body stores and maintains glycogen, the short-term energy reserve found in cells throughout the brain, muscles, and liver.
The first protein, laforin, acts as a quality-control enzyme. Its job is to remove phosphate groups from glycogen molecules, keeping them soluble and properly structured. The second protein, malin, helps regulate glycogen metabolism and clear out damaged proteins. When either gene is mutated, glycogen becomes overloaded with phosphate, develops abnormally long glucose chains, and loses its normal branching structure. The result is a substance that more closely resembles plant starch than human glycogen.
This malformed glycogen clumps into insoluble deposits called Lafora bodies, which accumulate inside cells of the brain, skin, liver, and muscle. In the brain, these deposits trigger inflammation and progressive damage to neurons, driving the seizures and cognitive decline that define the disease.
Early Symptoms and Who Is Affected
Lafora disease typically appears in late childhood or adolescence, most often between ages 12 and 17. Before symptoms begin, affected individuals develop normally with no obvious signs of illness. The first noticeable problems are usually seizures, particularly a type that originates in the visual processing areas of the brain and can cause temporary blindness, visual hallucinations, or flickering lights in the field of vision.
Myoclonus, sudden involuntary muscle jerks, appears early and gradually worsens. These jerks can be triggered by light, noise, or movement, and they increasingly interfere with daily tasks like writing, eating, and walking. Cognitive decline also begins early, with falling school performance often being one of the first warning signs parents notice.
How Symptoms Progress Over Time
The disease follows a relentless course. Within the first few years, generalized seizures become more frequent and harder to control. Intellectual decline accelerates into frank dementia. Speech becomes slurred and difficult to understand, a symptom called dysarthria, and coordination deteriorates as the brain regions controlling movement are affected.
In later stages, patients develop spasticity (stiffness in the limbs), significant visual loss, and in some cases psychosis. Half of all patients lose the ability to live independently within about six years of their first symptoms. By the advanced stage, most require full-time care and assistance with all basic activities.
A large analysis of 272 documented cases found that 93% of patients were alive five years after onset, 62% at ten years, and 57% at fifteen years. The median survival time was 11 years, which is somewhat longer than the frequently cited “death within a decade” figure. The most common causes of death are prolonged seizure episodes (status epilepticus), aspiration pneumonia, and other complications of severe neurological disability.
How Lafora Disease Is Diagnosed
Diagnosis relies on two main approaches: tissue biopsy and genetic testing. The classic method is a skin biopsy, typically taken from the armpit area. When the tissue is stained with a dye called Periodic Acid-Schiff (PAS), Lafora bodies appear as bright, carbohydrate-rich deposits clustered at the base of sweat glands. Finding these PAS-positive inclusion bodies in a patient with the right clinical picture confirms the diagnosis. The same deposits can be found in brain, liver, or muscle tissue, but a skin biopsy is far less invasive.
Genetic testing for mutations in the EPM2A and EPM2B genes provides a definitive molecular diagnosis and is increasingly used as the primary confirmatory tool. Because the disease is autosomal recessive, both copies of the affected gene must carry mutations. This means both parents are carriers, and each of their children has a 25% chance of inheriting the disease.
Current Treatment Options
No treatment currently exists that can stop or reverse the underlying accumulation of Lafora bodies. Management focuses on controlling seizures and maintaining quality of life for as long as possible. Anti-seizure medications can reduce the frequency and severity of episodes in the earlier stages, though seizures become progressively more difficult to manage as the disease advances. Supportive care, including physical therapy, nutritional support, and assistance with daily living, becomes increasingly important over time.
Experimental Therapies Targeting the Root Cause
One of the most promising experimental approaches directly targets the mechanism behind Lafora body formation. Researchers developed a synthetic molecule called an antisense oligonucleotide (ASO) that blocks the production of glycogen synthase, the enzyme responsible for building glycogen chains in the brain. In mouse models of Lafora disease, delivering this molecule into the spinal fluid stopped new Lafora bodies from forming, prevented existing ones from growing, and reduced brain inflammation. Because the treatment is delivered into the spinal fluid through a lumbar puncture, it reaches the brain without affecting glycogen production in the heart or other organs where glycogen is needed.
These results represent proof of principle that the disease process can be interrupted, and efforts are underway to translate this approach into a treatment for humans. For families affected by Lafora disease, this line of research offers the most concrete path toward a therapy that addresses the cause rather than just the symptoms.